A 42-year-old man with type 2 diabetes mellitus (HbA1c 9.2%) presents with sudden painless vision loss and floaters in both eyes. Dilated fundus examination reveals the findings marked as **A** in the diagram — neovascularization of the disc with vitreous hemorrhage. The patient has no prior history of retinal laser treatment. Which of the following is the most appropriate immediate management for this high-risk proliferative diabetic retinopathy?
A. Observation with monthly OCT imaging and tight glycemic control alone
B. Topical prostaglandin analogs and systemic acetazolamide for neovascular glaucoma prophylaxis
C. Immediate pars plana vitrectomy for vitreous hemorrhage clearance
D. Pan-retinal photocoagulation (PRP) with argon laser or intravitreal anti-VEGF therapy (aflibercept/ranibizumab)
Explanation
Why Pan-retinal photocoagulation (PRP) with argon laser or intravitreal anti-VEGF therapy is right
The findings marked A — neovascularization of the disc (NVD) with vitreous hemorrhage — define high-risk proliferative diabetic retinopathy (PDR) according to DRS criteria. The presence of any NVD with vitreous or preretinal hemorrhage is a direct indication for immediate treatment. PRP ablates ischemic peripheral retina to reduce VEGF drive and achieve neovessel regression in 60–80% of cases, reducing severe vision loss by 50% (DRS trial). Intravitreal anti-VEGF agents (aflibercept, ranibizumab, bevacizumab) are increasingly used as monotherapy or combined with PRP, offering faster neovessel regression and better visual field preservation; Protocol S (DRCR.net) demonstrated non-inferior visual outcomes with aflibercept monotherapy versus PRP at 2 years. Both are evidence-based first-line treatments for high-risk PDR. [AAO Diabetic Retinopathy PPP 2024; DRS, DRCR.net Protocol S]
Why each distractor is wrong
Immediate pars plana vitrectomy for vitreous hemorrhage clearance: Vitrectomy is reserved for non-clearing vitreous hemorrhage (>3 months duration) or when hemorrhage prevents adequate laser delivery. In acute presentation with high-risk PDR, PRP or anti-VEGF therapy should be initiated first to stabilize neovascularization; vitrectomy is not the immediate first-line intervention.
Topical prostaglandin analogs and systemic acetazolamide for neovascular glaucoma prophylaxis: While neovascular glaucoma is a known complication of PDR, these agents are treatment for established glaucoma, not prophylaxis. The immediate priority is to arrest neovascularization and prevent vision-threatening complications, not to preemptively treat a complication that may not develop.
Observation with monthly OCT imaging and tight glycemic control alone: High-risk PDR with NVD and vitreous hemorrhage is a sight-threatening emergency requiring immediate intervention. Observation alone without laser or anti-VEGF therapy risks rapid progression to tractional retinal detachment, neovascular glaucoma, and permanent vision loss. Glycemic control is essential but insufficient as monotherapy for established PDR.
High-YieldNEET PG
High-risk PDR (NVD ≥1/3 disc area, or any NVD with vitreous/preretinal hemorrhage, or NVE ≥1/2 disc area with hemorrhage) requires immediate PRP or anti-VEGF therapy—not observation or vitrectomy alone.
AAO Diabetic Retinopathy PPP 2024; DRS, DRCR.net Protocol S
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
